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E-mail: zoltan.ivics@pei.deThe Sleeping Beauty (SB) transposon system is a non-viral
gene delivery platform that combines simplicity, inexpensive
manufacture, and favorable safety features in the context
of human applications. However, efficient correction of
hematopoietic stem and progenitor cells (HSPCs) with non-
viral vector systems, including SB, demands further refine-
ment of gene delivery techniques. We set out to improve
SB gene transfer into hard-to-transfect human CD34+ cells
by vectorizing the SB system components in the form of min-
icircles that are devoid of plasmid backbone sequences and
are, therefore, significantly reduced in size. As compared to
conventional plasmids, delivery of the SB transposon system
as minicircle DNA is 20 times more efficient, and it is asso-
ciated with up to a 50% reduction in cellular toxicity in hu-
man CD34+ cells. Moreover, providing the SB transposase in
the form of synthetic mRNA enabled us to further increase
the efficacy and biosafety of stable gene delivery into hemato-
poietic progenitors ex vivo. Genome-wide insertion site
profiling revealed a close-to-random distribution of SB trans-
poson integrants, which is characteristically different from
gammaretroviral and lentiviral integrations in HSPCs.
Transplantation of gene-marked CD34+ cells in immunodefi-
cient mice resulted in long-term engraftment and hemato-
poietic reconstitution, which was most efficient when the
SB transposase was supplied as mRNA and nucleofected cells
were maintained for 4–8 days in culture before transplanta-
tion. Collectively, implementation of minicircle and mRNA
technologies allowed us to further refine the SB transposon
system in the context of HSPC gene delivery to ultimately
meet clinical demands of an efficient and safe non-viral
gene therapy protocol.M
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Gene therapy of hematopoietic stem and progenitor cells (HSPCs)
aims at the lifelong genetic correction of patients’ blood progenitors,
and it has been successfully applied in clinical settings to treat a
variety of monogenic diseases, including primary immunodefi-
ciencies.1 Along with undisputed therapeutic benefits achieved after
transplantation of genetically corrected autologous HSPCs, adverse
events of the treatment have been observed in some clinical trials
relying on gene delivery by gammaretroviral (gRV) vectors.2–5
Although highly efficient in HSPC transduction, gRV vectors used
in those trials unfortunately turned out to be genotoxic in the
long term. The undesired insertional mutagenesis manifested in
some of the patients by the development of leukemia, thereby
raising serious safety concerns with the use of these vectors. As a
consequence, substantial work has been dedicated to crafting
advanced and safer vector systems, including self-inactivating
(SIN)-gRV and SIN-lentiviral (SIN-LV) vectors devoid of
enhancer/promoter sequences in their 30 long terminal repeats
(LTRs).6–8 On the other hand, non-viral gene delivery by the
Sleeping Beauty (SB) transposon system, with a close-to-random
integration profile9–13 and negligible transcriptional activities associ-
ated with the transposon-specific inverted terminal repeats (ITRs),14
has been developed as an alternative to viral vectors commonly usedolecular Therapy Vol. 26 No 4 April 2018 ª 2018 The Authors. 1137
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapyin gene therapy trials. However, some technical challenges to the
clinical implementation of the SB system have remained unmet.
The SB gene delivery technology is typically provided in the form of
two plasmid DNA-based vectors: the first carrying a transposon unit
defined by SB’s ITRs that flank a gene of interest to be inserted into
the genome, and the second encoding the SB transposase, the enzy-
matic component of the system. Upon its transient expression, the
SB transposase recognizes and binds the ITRs and excises the trans-
poson unit from the donor construct and integrates it into a genomic
locus, thereby leading to persistent expression of the gene of interest
in genetically modified cells and their progeny. Since its reactivation
by means of reverse mutagenesis from fossil sequences found in fish
genomes,15 the activity of the SB transposon system has been signif-
icantly enhanced by molecular evolution, resulting in a superior,
hyperactive variant of the SB transposase called SB100X.16 This
non-viral gene delivery tool has been successfully employed for versa-
tile purposes of genome manipulation in animals (reviewed in Ivics
et al.17), including functional cancer gene screens (also reviewed18,19),
and germline gene transfer in experimental animals.20–22 In gene
therapy applications, the SB transposon system has been successfully
adapted to render sustained expression of therapeutic transgenes for
the treatment of a variety of animal disease models, following both
ex vivo and in vivo gene delivery (reviewed elsewhere23–26). After
promising preclinical validation, it finally entered the clinics in the
context of cancer gene therapy aiming at redirecting T cell-mediated
immune responses toward B cells malignancies.27 Stable delivery of a
CD19-specific chimeric antigen receptor (CAR) to T cells by applying
this novel non-viral approach has been evaluated in ongoing hu-
man trials as efficacious and safe, and the manufacture of anti-
tumor cell products of clinical grade has been assessed as cost effective
and less laborious than that achieved by recombinant retroviral
transduction.13,28–30
Implementation of the SB transposon system for gene therapy of the
HSPC system is, however, hampered by a low efficiency of plasmid
DNA delivery into stem cells in general.16,31 Although it has been
greatly improved by the use of nucleofection, an advanced technique
of electroporation achieved by a combination of electrical pulses and
cell type-specific solutions facilitating more efficient transfer of exog-
enous nucleic acids to both cytoplasm and nucleus,32,33 non-viral
gene delivery into HSPCs is still considered to be inefficient when
compared with viral technologies. In addition, such a physical way
of naked plasmid DNA delivery into HSPCs results in an excessive
loss of cell viability, and the observed cytotoxicity increases propor-
tionally to plasmid DNA load.34 Moreover, unmethylated CG
dinucleotide (CpG) motifs present in the bacterial backbone of con-
ventional plasmid vectors have been postulated to trigger immuno-
genic responses against foreign DNA.35–37 Finally, the presence of
an antibiotic resistance gene typically present in plasmid vectors rai-
ses additional safety concerns in the context of gene therapy.
In efforts to address the limitations of non-viral gene transfer into
HSPCs, we modified the conventional plasmid DNA-based form of1138 Molecular Therapy Vol. 26 No 4 April 2018the SB transposon system by employing the minicircle (MC) technol-
ogy. MCs are supercoiled minimal expression cassettes developed for
application in non-viral gene delivery. They are derived from their
parental plasmids via an intramolecular recombination process, dur-
ing which the majority of bacterial backbone sequences are depleted
from the vector.38–40 The MC vectors are, therefore, significantly
reduced in size, and, as a consequence, they have been shown to
enhance gene delivery into a variety of cell lines in vitro38,41,42 and
into the liver,43,44 lungs,45 muscles,41,46 and tumors42,46 in vivo.
MCs have served as a more efficient and advanced non-viral delivery
method for targeted genetic modification using zinc-finger nucle-
ases,47 generation of induced pluripotent stem cells,48 in vaccination
therapy to enhance HIV-specific immune responses,49 and in blood-
based cancer detection.50 The improved potential of MC DNA-based
delivery was also evidenced in a preclinical gene therapy for episomal
treatment of mucopolysaccharidosis type I44 and familial hypercho-
lesterolemia.51 A proof-of-concept study on the SB transposon system
coupled with the MC DNA technology was performed in the HeLa
cell line, and lipofection-based intracellular delivery of the improved
version of the system resulted in robust SB transposition and trans-
gene integration.52 Finally, implementation of the MC technology
has recently been shown to enable superior stable gene transfer effi-
ciencies in human T cells for advanced CAR-T cell engineering
with SB transposon vectors.13
In the present work, we generated the SB transposon system in the
form of MC DNA of high purity, and we successfully validated its
enhanced integrative properties in human HSPCs. Moreover, we
further refined our non-viral gene delivery strategy by supplying
the SB100X transposase as an mRNA, as nucleofection of HSPCs
with mRNA was shown to cause only marginal loss of cell viability
compared to nucleofection with plasmid DNA.53 A concept of SB
transposase-encoding mRNA to be efficiently co-delivered with an
SB transposon unit to somatic cells was originally tested in a
mammalian cell line in vitro and in mouse liver in vivo, using
an early version of the SB transposase called SB11.54,55 For the
purpose of improved mRNA-based delivery of the hyperactive
SB100X transposase into HSPCs, we adopted a novel technology
of chemically modified mRNA characterized by enhanced stability
and lower immunogenicity called Stabilized Non-Immunogenic
Messenger RNA (SNIM.RNA).56 To our knowledge, it is the first
report investigating the performance of MC DNA and synthetic
mRNA platforms in human HSPCs in the context of non-viral,
SB transposon system-mediated genome modification for persis-
tent transgene delivery, and as such it presents a significant
advance for SB transposon technology for clinical blood stem
cell gene therapy.
RESULTS
Increased Cell Viability after Nucleofection with Minicircle DNA
and Minicircle DNA/SNIM.RNA Platforms for Intracellular
Delivery of the Sleeping Beauty Transposon System
Nucleofection of HSPCs is associated with significantly reduced
cell viability, which, in turn, affects the overall yield of genetically
Figure 1. Minicircle-Based Sleeping Beauty
Transposon Vectors and Cellular Toxicity of Gene
Delivery 2 Days Post-nucleofection in CD34+ Cells
(A) MC vectors encoding the transposon or the transposase
component of the SB system are derived from parental
plasmids by intramolecular recombination. The parental
transposon plasmid carries a CAGGS-Venus expression
cassette (green) flanked by the ITRs of SB (purple), plasmid
backbone sequences (red), and recombination sites (black).
The parental transposase plasmid carries a CMV-SB100X
expression cassette (blue), plasmid backbone sequences
(red), and recombination sites (black). MCs have a markedly
reduced size and lack most of the plasmid backbone se-
quences. (B) Percentage of DAPI-negative cells determined
by flow cytometry. Data are expressed as means ± SEM
(n = 5–6 per group). Asterisks indicate significant differences
as determined by Student’s t test (*p < 0.05 and **p < 0.01;
10 + 5 or 10 + 10 indicate the mg of the MC-Venus and the
SB-transposase used during nucleofection).
www.moleculartherapy.orgmodified cells. In our efforts to improve non-viral gene delivery into
HSPCs for gene therapy purposes, we modified the conventional
plasmid DNA form of the SB transposon system by applying MC
DNA and SNIM.RNA technologies. The produced SB MCs were
markedly reduced in their size compared to conventional plasmid
DNA vectors, with 3.4 kb obtained for the MC-SB transposon
(MC.T2-CAGGS-Venus) that carried a Venus reporter cassette and
2.3 kb for a CMV promoter-driven SB transposase (MC.SB100X) vec-
tor (Figure 1A; Figure S1).
We nucleofected human CD34+ cells with the MC.T2-CAGGS-
Venus and MC.SB100X constructs, and we compared their perfor-
mance with that of a conventional plasmid DNA form of thesystem. As a baseline condition, we opted for
using 10 mg SB transposon and 5 mg SB transpo-
sase construct per 106 cells, as it was the optimal
mass combination of both vectors in terms of
overall efficiency of gene delivery and cytotoxicity
(data not shown). To assess cellular toxicity, we
implemented staining with DAPI followed by
flow cytometry, by which the percentage of
DAPI-negative and, thus, viable cell population
was estimated at day 2 post-delivery.
As depicted in Figure 1B, a slight cellular toxicity
was induced by nucleofection itself (mock control),
but it was more pronounced when exogenous DNA
was included in the reaction. Cell viability was
compromised the most when the SB transposon
system was introduced in the form of conventional
plasmid DNA vectors, with only 61.3% ± 8.5% of
DAPI-negative (i.e., live) cells detected within the
total cell population. The highest cell viability
(86.2% ± 3.0% of viable cells, a 1.4-fold increase)
was observed after the delivery of MC DNA inamounts equimolar to the plasmid DNA-based SB transposon sys-
tem. Equimass amounts of MC DNA vectors resulted in a 1.2-fold in-
crease in the percentage of viable cells (73.5% ± 7.4%) compared to
plasmid DNA, and this effect was maintained with SNIM.RNA en-
coding the SB100X transposase, with 76.2% ± 6.6% and 73.6% ±
7.3% of viable cells measured in the MC/SNIM.RNA-SB 10 + 5 and
MC/SNIM.RNA-SB 10 + 10 conditions, respectively. Respective
cellular toxicities associated with nucleic acid delivery by nucleofec-
tion were also assessed and confirmed by trypan blue (TB) staining
and exclusion of dead cells following automated counting of un-
stained and, therefore, viable cells (data not shown). We conclude
that excessive loss of HSPC viability is mostly related to the presence
of plasmid DNA in the reaction and that this cellular toxicity can beMolecular Therapy Vol. 26 No 4 April 2018 1139
Figure 2. Efficiency of Transient Gene Expression following Minicircle-
Based Delivery of Sleeping Beauty Transposon Vectors in CD34+ Cells
(A and B) The (A) percentage and (B) mean fluorescence intensity (MFI) of Venus+
cells determined by flow cytometry 2 days post-delivery. (C) Overall efficiency of
transient gene delivery and expression calculated by multiplying the percentage of
Venus+ cells and their MFIs. Data are expressed as means ± SEM (n = 5–6 per
group). Asterisks indicate significant differences as determined by Student’s t test
(*p < 0.05 and **p < 0.01).
Molecular Therapysignificantly reduced by implementing the MC DNA platform alone
or in combination with SNIM.RNA technology for delivery of the SB
transposon system.1140 Molecular Therapy Vol. 26 No 4 April 2018Improved Intracellular Delivery of the Sleeping Beauty
Transposon System by Minicircle Vectors into CD34+ Cells
High levels of genomic modification of hard-to-transfect HSPCs by
means of a non-viral integrative technology necessitate efficient intra-
cellular delivery of the implemented vector system. Vector size is a
potent modulator of this parameter, and smaller constructs tend to
cross the cell membrane and reach the nucleus more efficiently
than larger ones.57,58 In light of these facts, we implemented the
MC DNA platform in order to significantly reduce SB transposon
and transposase vectors in their size and, thus, enhance their rate of
intracellular delivery, with a final goal of achieving sufficient levels
of HSPC genome modification to be relevant for clinical gene therapy
purposes. We examined the levels of intracellular delivery of SB
vectors at day 2 post-nucleofection (transient gene delivery) by flow
cytometry. The performance of the MC DNA platform alone or in
combination with SNIM.RNA technology was compared with that
of plasmid DNA in terms of percentage and mean fluorescence inten-
sity (MFI) of Venus+ cells.
Whereas only 44.7% ± 2.2% of cells transiently expressing Venus
could be obtained using standard plasmid DNA vectors, this value
was markedly higher for the MC DNA platform, yielding overall
transient gene delivery efficiencies of 74.9% ± 1.2% and 64.1% ±
2.9% in an equimass and equimolar comparison with the plasmid
DNA system, respectively (Figure 2A). Moreover, improved trans-
fection of MC vectors was also reflected by the MFI of Venus+ cells.
Specifically, plasmid DNA was the least efficacious and led to MFI
rates of only 1,516 ± 154 (Figure 2B). There were 2.6- and 1.7-fold
increases in MFI values achieved in equimass (4,005 ± 264) and
equimolar (2,581 ± 247) conditions, respectively. Interestingly,
although the same type (MC DNA) and amount (10 mg) of the
SB transposon vector was implemented in three different delivery
variants (MC-SB mass equivalent, MC/SNIM.RNA-SB 10 + 5, and
MC/SNIM.RNA-SB 10 + 10), slightly different MFI values were
seen in those samples, with higher values obtained with SNIM
RNA (MC/SNIM.RNA-SB 10 + 10, 5,870 ± 550; and MC/
SNIM.RNA-SB 10 + 5, 5,239 ± 364). When the overall efficiency
of transgene expression (percentages of Venus+ cells multiplied by
their MFI values) was assessed, a very pronounced improvement
was seen for both MC DNA only or for the MC DNA/SNIM.RNA
combination (Figure 2C). More specifically, this value was 2.5-fold
(167,931 ± 24,114) and 4.4-fold (300,531 ± 22,234) higher for
MC DNA in an equimolar and equimass comparison with plasmid
DNA (68,441 ± 9,463), respectively. Advantageous gene transfer
promoted by MC DNA was even more striking in samples with
SNIM.RNA implemented for SB100X transposase delivery, with
6.1-fold (417,189 ± 33,956) and 6.8-fold (468,790 ± 53,083) in-
creases in relative transient gene delivery levels detected in the
MC/SNIM.RNA-SB 10 + 5 and MC/SNIM.RNA-SB 10 + 10 sam-
ples, respectively. Taken together, the MC DNA platform alone or
in combination with SNIM.RNA technology is capable of delivering
the SB transposon system into HSPCs significantly more efficiently
than conventional plasmids, suggesting that this improved platform
would also result in enhanced efficacies of stable transposition.
Figure 3. Long-Term Gene Expression following
Minicircle-Based Delivery of Sleeping Beauty
Transposon Vectors in CD34+ Cells
(A and B) The (A) percentage and (B) mean fluorescence
intensity (MFI) of Venus+ cells determined by flow cy-
tometry 15 days post-delivery. (C) Overall efficiency of
gene expression calculated by multiplying the percentage
of Venus+ cells and their MFIs. (D) Relative transposition
efficiency determined by the percentage of Venus+ cells
at day 2 post-nucleofection that retained Venus expres-
sion at day 15. Data are expressed as means ± SEM
(n = 5–6 per group). Asterisks indicate significant differ-
ences as determined by Student’s t test (*p < 0.05 and
**p < 0.01).
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System in the Form of a Minicircle DNA/SNIM.RNA Combination
into CD34+ Cells
Our main goal behind implementing the MC DNA and SNIM.RNA
technologies was to improve non-viral stable gene integration/expres-
sion in hard-to-transfect HSPCs. To evaluate vector performance in
terms of SB-mediated genomemodification, nucleofected CD34+ cells
were maintained in culture for a prolonged period of time. In the
absence of transposase, as expected, the initial (transient) levels of
Venus reporter expression gradually diminished during cell expan-
sion post-nucleofection, with plasmid and MC vectors most likely
undergoing cellular degradation by cytosolic nucleases59 and being
successively excluded from cell cultures with each cell division. The
slowly attenuated residual plasmid and MC DNA-specific transgene
expression was, therefore, undetectable by flow cytometry beyond
14–19 days post-delivery (Figure S2). However, in the presence of
transposase, following an initial decline until day 12 post-nucleofec-
tion, Venus expression was stably maintained thereafter for at least
62 days after nucleofection (end of experiment) (Figure S2), likely
because the Venus signal was derived from genomically integrated
transgenes.
The least efficient plasmid DNA-based delivery of the SB transposon
system into CD34+ cells also resulted in very low numbers of Venus-
expressing cells at day 15 post-nucleofection (only 0.8% ± 0.2% with
an overall MFI of 405 ± 63; Figures 3A and 3B, respectively). In
contrast, implementation of the MC vectors in equimolar amounts
resulted in a significantly higher representation of Venus-expressingMocells (6.1% ± 0.7%) carrying at least one copy of
the SB transposon in their genomes (Figure 3A).
Improved SB integration from MC vectors was
accompanied by a 6.8-fold higher MFI of Venus
signal (2,754 ± 403) (Figure 3B). As expected, in
a mass-to-mass comparison of the two delivery
platforms, the outperformance of MC DNA
over conventional plasmids was even more
apparent, giving rise to 16.0% ± 1.6% of
Venus-expressing cells (Figure 3A) with an
MFI of 5,231 ± 726 (Figure 3B). Finally, themost significant improvement in stable gene delivery could
be achieved when the MC-based SB transposon was comple-
mented with SNIM.RNA as a transient source of the SB100X transpo-
sase, with 25.5% ± 1.7% and 34.4% ± 1.7% of Venus+ cells (Figure 3A)
with MFIs of 4,207 ± 523 and 5,117 ± 410 detected in the MC/
SNIM.RNA-SB 10 + 5 and MC/SNIM.RNA-SB 10 + 10 samples,
respectively (Figure 3B).
Similar to the analysis of transient gene expression (Figure 2), the
overall efficiency of transgene expression at day 15 post-transfection
(percentages of Venus+ cells multiplied by their MFI values) in
expanded, CD34+ cell-derived populations revealed a dramatic out-
performance of our dual MC DNA/SNIM.RNA delivery approach
over conventional plasmid DNA vectors (Figure 3C). The calculated
overall efficiency of transgene expression reached values of 106,793 ±
12,647 and 175,297 ± 14,299 in the case of MC/SNIM.RNA-SB 10 + 5
and MC/SNIM.RNA-SB 10 + 10 delivery variant, respectively (Fig-
ure 3C). The SB100X transposase provided in the form of MC
DNAwas in general less efficient than SNIM.RNA, with overall values
of 84,680 ± 15,070 and 16,720 ± 2,810 determined for the mass and
molar equivalents of the plasmid DNA platform, respectively. The
MC vectors, however, were still far more efficient than plasmid
DNA at supporting SB-mediated HSPC genome modification. The
implementation of the SB transposon system in the form of con-
ventional plasmid DNA yielded overall combined values of
stable gene delivery into CD34+ cells of only 290 ± 69, which
was 600-fold less efficient than that achieved in our best condition
(MC/SNIM.RNA-SB 10 + 10) (Figure 3C).lecular Therapy Vol. 26 No 4 April 2018 1141
Figure 4. Stable Gene Transfer and Expression Mediated by Sleeping
Beauty Transposons in Committed Hematopoietic Progenitor Cells
(A) Representative images of colonies generated after culture of nucleofected
cells in methylcellulose medium enriched with a cytokine cocktail supporting the
formation of burst-forming unit-erythroid (BFU-E), colony-forming unit-erythroid
(CFU-E), colony-forming unit-granulocyte, macrophage (CFU-GM), and colony-
forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM). (B)
Percentage of colonies stably expressing Venus after MC DNA only and MC DNA/
SNIM.RNA-based delivery of the SB transposon system. Data are expressed as
means ± SEM (n = 3 per group). Asterisks indicate significant differences as
determined by Student’s t test (*p < 0.05 and **p < 0.01).
Molecular TherapyAnother way of assessing the efficiency of the SB transposon system
for stable gene delivery is to calculate the fraction of cells that were
initially Venus+ at day 2 post-transfection that retained Venus expres-
sion after prolonged cell expansion (i.e., at day 15, when almost no
Venus expression was observed in cells transfected without the trans-
posase; Figure S2). TheMCDNA platformwas associated with signif-
icantly higher levels of stable gene transfer when compared to
conventional plasmid DNA, with 21.4% ± 2.2% and 9.5% ± 0.7% of
cells retaining the Venus signal in equimass and equimolar condi-
tions, respectively (Figure 3D). In contrast, only 1.8% ± 0.5% of the
initially Venus+ cell fraction underwent transposition after plasmid1142 Molecular Therapy Vol. 26 No 4 April 2018DNA-based delivery of the SB transposon system and expressed
Venus at day 15 post-nucleofection. The SB100X transposase
provided in the form of SNIM.RNA supported the highest level of sta-
ble transgene expression at 32.1% ± 2.0% and 43.4% ± 2.4% in
the MC/SNIM.RNA-SB 10 + 5 and MC/SNIM.RNA-SB 10 + 10 con-
ditions, respectively, highlighting the advantage of our dual MC/
SNIM.RNA-SB delivery approach (Figure 3D).
Sleeping Beauty-Mediated Genetic Modification of CD34+ Cells
Is Not Restricted to Specific Committed Progenitors
To assess whether stable genetic modification mediated by nucleofec-
tion with the different SB platforms was restricted to specific hemato-
poietic progenitor cells, we performed colony-forming unit-culture
(CFU-C) assays in vitro (Figure 4A) using our three best delivery var-
iants, namely MC-SB 10 + 5, MC/SNIM.RNA-SB 10 + 5, and MC/
SNIM.RNA-SB 10 + 10.
In each of three independently performed CFU-C assays, the
presence of Venus+ cells could be demonstrated in burst- and col-
ony-forming units of erythroid cell type (BFU-E/CFU-E), colony-
forming units with granulocytes and macrophages (CFU-GM),
and mixed colony-forming units of myeloid and erythroid type
(CFU-GEMM) following MC DNA- and MC DNA/SNIM.RNA-
based delivery of the SB transposon system. Although no apparent
differences were seen in the overall CFU potential of the cells
following nucleofection with the three different delivery variants
(Figure S3), differences were clearly visible with regard to the contri-
bution of Venus+ CFUs to the total CFU counts (Figure 4B). As pre-
viously seen in liquid cultures, the SB transposon system in the form
of MC DNA (equimass condition, MC-SB 10 + 5) was associated
with the lowest efficiency to generate Venus+ colonies (21.7% ±
2.2% of CFUs with detectable long-term Venus expression,
including 21.0% ± 2.7%, 24.7% ± 2.7%, and 15.0% ± 1.8% of Venus+
BFU-E/CFU-E, CFU-GM, and CFU-GEMM, respectively). The
MC/SNIM.RNA platform was more efficient at supporting SB trans-
position, which resulted in 29.1% ± 2.5% of Venus-expressing CFUs
in the MC/SNIM.RNA 10 + 5 sample. In detail, there was a 1.3
(27.1% ± 3.7%), 1.3 (32.7% ± 2.6%), and 1.6 (24.6% ± 2.8%) times
more frequent appearance of SB-modified colonies of erythroid
(BFU-E/CFU-E), granulocyte/macrophage (CFU-GM), and mixed
(CFU-GEMM) type, respectively, observed in this sample when
compared to the MC-SB 10 + 5 condition. Similar to the results ob-
tained after flow cytometry-based analysis of stable gene delivery,
the MC/SNIM.RNA-SB 10 + 10 combination of the SB transposon
system appeared to be the most efficient at genomic modification of
hematopoietic progenitors, and it yielded on average 41.1% ± 3.4%
of Venus-expressing colonies (a 1.9-fold increase compared to the
MC-SB 10 + 5 condition), with 40.1% ± 4.5%, 42.6% ± 2.4%, and
38.8% ± 5.7% of BFU-E/CFU-E, CFU-GM, and CFU-GEMM,
respectively, bearing the Venus signal. In aggregate, HSPC genome
manipulation by the SB transposon system, and most significantly
with the MC DNA/SNIM.RNA vector combination, yields highly
efficient transgene expression in committed progenitor cells of the
erythroid and myeloid lineages.
Figure 5. Vector CopyNumbers inSleeping Beauty-EngineeredCD34+Cells
(A) Determination of vector copy number (VCN) in bulk cells cultured for 3 weeks in
liquid culture. Data are expressed asmeans±SEM (n= 5–6per group). (B)Correlation
between VCN determined in bulk cells and relative stable gene delivery efficiency
defined as percentage Venus+ cells multiplied with their MFIs. (C) VCN determined in
CFUs. r, Pearson coefficient of the correlation; p, significance coefficient.
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Delivery Platforms Enable Efficient Transgene Integration in
CD34+ Cells
Next, we were interested in the numbers of SB transposon integra-
tions obtained per HSPC genome, another parameter reflecting theefficiency of persistent gene delivery. qPCR was performed using un-
selected bulk cell populations (containing both Venus+ and Venus
cells) harvested 3 weeks post-nucleofection. For these analyses, three
of our best and, therefore, most relevant delivery variants, MC-SB
10 + 5, MC/SNIM.RNA-SB 10 + 5, and MC/SNIM.RNA-SB
10 + 10, were chosen.
The average vector copy number (VCN) per diploid genome was
0.24 ± 0.05 in the MC-SB 10 + 5 condition (Figure 5A). With
SNIM.RNA, 0.41 ± 0.15 and 0.46 ± 0.07 copies of the integrated trans-
poson per cell were detected upon MC/SNIM.RNA-SB 10 + 5 and
MC/SNIM.RNA-SB 10 + 10 delivery, respectively. The tendency to-
ward higher VCNs is, thus, associated with the higher efficiency of
stable gene transfer observed in both DNA/SNIM.RNA-SB delivery
variants. Indeed, as shown in Figure 5B, there was a significant corre-
lation between the obtained VCNs/genome and the relative efficiency
of stable gene delivery (as defined bymultiplying percent Venus+ cells
by their MFIs at day 15 post-delivery).
To restrict the analysis to only those cells in which transposition defi-
nitely took place, individual Venus+ CFUs generated in methylcellu-
lose medium were picked, and genomic DNA was isolated and
subjected to droplet digital PCR. This qPCR analysis allowed us to
precisely determine the number of integrated vector copies at the
cell clonal level despite very limited amounts of DNA present in the
reaction. These analyses revealed that 64% of the analyzed colonies
carried 1 copy of the Venus transgene in the genome, regardless of
the vector combination applied to deliver the SB transposon system
(Figure 5C). More specifically for the MC-SB 10 + 5 delivery variant,
12 of 18 colonies harbored 1 copy of the SB transposon per diploid
genome. Two copies could be found in 3 independent colonies, and
colonies with 3, 4, and 5 copies were each represented only once. In
the MC/SNIM.RNA-SB 10 + 5 delivery variant, the obtained VCN/
genome was more homogeneous; the absence of colonies with
VCN/genome >2 correlated with slightly lower MFI values recovered
in this delivery variant (Figure 3B). The most effective delivery form
of the SB transposon system (MC/SNIM.RNA-SB 10 + 10) gave rise
to 11 colonies of 18 analyzed with a single-copy transposon integra-
tion, 6 colonies containing 2–4 copies/genome, and a single colony
with up to 7 copies of the Venus cassette per genome (Figure 5C).
In sum, quantitative analysis of VCNs in bulk cell populations and in
individual colonies complements the data on stable gene expression
determined by flow cytometry and clonogenic assays. Importantly,
these analyses show that highly efficient gene delivery by theMC plat-
form, either alone or in combination with the SNIM.RNA technology,
is not accompanied by excessive copy numbers of integrated trans-
genes per genome.
Random Profile of Sleeping Beauty-Mediated Transgene
Integration in CD34+ Cells
Non-targeted insertions of therapeutic foreign DNA into the genome
are subject to position effects, which may alter cell physiology and
lead to malignant transformations. To assess the biosafety of the SBMolecular Therapy Vol. 26 No 4 April 2018 1143
Figure 6. Genome-wide Distribution of Sleeping
Beauty Transposon, MLV-Derived
Gammaretroviral, and HIV-1-Derived Lentiviral
Integrations in CD34+ Cells
(A) Distribution of MLV, HIV, and SB insertions in func-
tional genomic segments of human G-CSF-mobilized
HSPCs. Numbers show relative enrichment above the
random frequency (set to 1). Color intensities depict the
degree of deviation from the expected random distribu-
tion. The cladogram was drawn on the basis of row
means. (B) Distribution of vector insertion sites around
transcriptional start sites (TSSs). The gray line corre-
sponds to random insertion frequency. (C) Correlation
between integration rates and transcriptional activity of
the insertion sites. The numbers of the x axis stand for
groups of transcription units of increasing activity in hu-
man HSPCs. Negative and positive values of the y axis
indicate under- and over-representation in fold change
over the random expected insertion frequency, shown
as 1. (D) Representation of vector insertion sites cosr-
responding to genomic safe harbor criteria. The numbers
represent percent values of all insertions of the corre-
sponding group. Color intensities imply deviation from an
ideal 100% representation. (E) Overall representation of
insertion sites in genomic safe harbors.
Molecular Therapyvector system, we performed a genome-wide insertion site profiling of
SB integrations in human hematopoietic progenitors after MC DNA
and MC DNA/SNIM.RNA-based delivery by massively parallel
sequencing. PCR-based insertion site libraries were generated from
genomic DNA isolated from CD34+ cells at least 3 weeks post-
nucleofection. The bioinformatic analysis using conservative filtering
resulted in 875 and 14,127 unique insertion sites derived from the
MC DNA and MC DNA/SNIM.RNA delivery methods, respectively.
Since the difference of the transposase source in the two experimental
conditions was of delivery method (DNA versus RNA) and not of
type (amino acid composition), the two insertion site sets were united
into a single pool for the downstream analysis. Then, we compared
the SB integration profile with published or ad hoc-generated datasets
of 32,574 gRV60 and 58,294 HIV-derived lentiviral vector integration1144 Molecular Therapy Vol. 26 No 4 April 2018sites in human cord blood-derived HSPCs, us-
ing a computationally generated random inte-
gration dataset as a control.
At the DNA sequence level, TA dinucleotides
positioned at the center of an 8-bp palindromic
AT repeat, a canonical molecular signature of
SB chromosomal integration,9 were found as
highly preferred sites of SB integration (Fig-
ure S4). Next, we profiled the SB insertions in
functional genomic segments. These are regions
of co-occurring epigenetic signal patterns,
which were clustered together computationally,
to comprise various functional partitions
of the human genome.61 We used 15- and25-state chromatin models of granulocyte colony-stimulating factor
(G-CSF)-mobilized primary HSPCs to compare the SB insertion pro-
file to the distribution of murine leukemia virus (MLV)-derived gRV
and HIV-derived lentiviral insertions in the human genome (Fig-
ure 6A; Figure S5). In agreement with earlier findings, we found
that, while MLV and HIV insertions accumulated in loci flanking
transcriptional start sites (TSSs) and within actively transcribed
genes, respectively, SB insertions showed only a minor bias toward
these genomic segments. Moreover, of the three studied gene vector
systems, the overall profile of SB is the closest to a random
distribution.
Next, we aimed at comparing the propensity of gene vectors to
interact with host transcription by studying the integration frequency
www.moleculartherapy.orgof MLV, HIV, and SB around TSSs and within transcription units of
human HSPCs (Figures 6B and 6C). We found that, while MLV in-
sertions peaked within a 4-kb window centered on TSSs, HIV had
an integration bias away from the TSSs both to the upstream and to-
ward the bodies of genes. On the contrary, the frequency of SB inte-
grants in these segments was close to a distribution expected by
random chance (Figure 6B). When the insertion frequencies in tran-
scription units were related to the transcriptional activity at the inser-
tion sites, we found that, although all the vectors showed a tendency
to integrate into actively transcribed chromatin, SB insertions showed
the least deviation from the random insertion rates both within silent
and in highly expressed genes (Figure 6C). Moreover, in agreement
with the tendency of the HIV and MLV to integrate within and in
the upstream proximity of expressed genes, we found that the viral
vectors had a larger propensity to hit genomic regions associated
with human hematopoietic disorders than SB transposon vectors
(Figure S6).
Integration of therapeutic gene constructs into genomic safe harbors
(GSHs) in the human genome would prevent insertional mutagenesis
and the associated risks of oncogenesis in gene therapy. GSHs are re-
gions of the human genome that support predictable expression of
newly integrated DNA without adverse effects on the host cell.
GSHs can be bioinformatically allocated to chromosomal sites or re-
gions if they satisfy the following criteria: (1) no overlap with tran-
scription units, (2) at least 300-kb distance to cancer-related genes
and (3) microRNA genes, and (4) at least 50-kb distance from TSSs
of genes and (5) regions outside of ultraconserved regions.62,63 Since
transcription units can extend to long chromosomal territories, a hy-
pothetical gene vector even with completely random insertion site
distribution would integrate the transgene outside of genes with
only 58% probability (Figure 6D). We found that the biases of the
MLV and HIV integration machinery toward expressed genes
decreased the fraction of non-genic viral insertions to 41% and
20%, respectively. On the contrary, approximately 47% of all SB inser-
tions were found outside of genes in HSPCs. Figure 6D also depicts
that the insertion profile of SB segregates away from the insertion dis-
tribution ofMLV andHIV and had a close-to-random pattern. In line
with these observations, studying the insertion frequencies in the
intersection of all five GSH criteria showed that SB has the safest ex-
pected insertion distribution of the tested vectors in a therapeutic
context (Figure 6E). Collectively, our analysis on vector biosafety pre-
dicts a safer, thus favorable transgene insertion profile for SB over
MLV- and HIV-based vectors in therapeutic gene transfer in human
HSPCs.
Improved SB Gene Delivery Platforms Enable Efficient In Vivo
Transgene Expression in Human Hematopoietic Cells
Repopulating Immunodeficient Mice
Next we addressed the ability of the newly developed, MC-based SB
gene delivery platforms to genetically modify human hematopoietic
repopulating cells capable of conferring in vivo expression after trans-
plantation into immunodeficient mice. Due to the toxicity (Figure 1)
and relatively low efficiency of stable gene transfer (Figure 3) associ-ated with the use of plasmid DNA in vitro, only the MC constructs
were considered in these experiments. After nucleofection, cells
were maintained for either 1–2.5 days (black dots) or 4–8 days
(white dots) in vitro (Figure 7), with the purpose of minimizing
potential homing defects associated with cell nucleofection. There-
after, numbers equivalent to 0.7–1  106 nucleofected cells were
transplanted into NOD-scid IL2Rgnull (NSG) mice irradiated with
1.5 Gy, as described in Materials and Methods.
As shown in Figure 7A, when recipients were transplanted with con-
trol CD34+ cells, either not nucleofected (black and white dots) or nu-
cleofected without DNA (gray dots), donor engraftment levels higher
than 10% were observed in all instances (mean level of hCD45+ cells:
37.8%). On the contrary, when cells were nucleofected with SB MCs
and the transposase (either used as MCDNA or mRNA), a significant
number of NSG recipients showed graft failure (levels of hCD45+
cells: <1%). This was most evident when nucleofected cells were incu-
bated for only 1–2.5 days (9 of 22 recipients failed to engraft human
CD45+ cells; black dots) compared to samples incubated for 4–8 days
(11 of 12 recipients showed evident engraftment with hCD45+ cells;
white dots). Strikingly, when CD34+ cells were nucleofected with
the MC transposon plus the transposase mRNA and then maintained
for 4–8 days in culture, all transplanted mice showed evident hemato-
poietic reconstitution, which resulted in engraftment levels very
similar to those observed in mice transplanted with control CD34+
cells (44.8% and 37.8%, respectively; p < 0.05).
Our results also demonstrated the expression of the Venus transgene
in human hematopoietic cells engrafting the NSG mice (Figure 7B).
Although the presence of Venus+ cells was observed in all groups of
transplanted mice, the infusion of nucleofected cells that were pre-
incubated for 4–8 days facilitated the expression of the marker in
every transplanted mouse (mean percentage of hCD45+ cells positive
for Venus expression: 13.44% and 13.42% in the MC-SB and the MC/
SNIM.RNA-SB groups, respectively; p < 0.05).
To confirm that the expression of the Venus marker gene was not
restricted to specific human hematopoietic lineages, the presence of
Venus+ cells was investigated in myeloid and lymphoid cells engraft-
ing the bone marrow (BM) of transplanted NSGmice (see data in Fig-
ure 7C and representative analyses in Figure S7). Data in Figure 7C
clearly demonstrate the presence of Venus+ cells in both the human
myeloid (CD33+) and the lymphoid (CD19+) cells. Even more, our
data clearly show the presence of CD34+ cells that expressed the
marker gene, demonstrating transposition in primitive human he-
matopoietic repopulating cells that facilitated the in vivo expression
of the transgene in engrafted cells. Consistent with overall engraft-
ment levels (Figure 7A) and Venus expression (Figure 7B), the infu-
sion of CD34+ cells that had been nucleofected with MC-SB plus
transposase mRNA and pre-incubated for 4–8 days resulted in
the most consistent results of gene expression in all tested human
hematopoietic lineages. Although differences in the proportion
of Venus+ cells could not be established between the different
groups of transplanted mice, the presence of Venus+ cells could beMolecular Therapy Vol. 26 No 4 April 2018 1145
Figure 7. Analysis of Engraftment and Gene Expression in NSG
Immunodeficient Mice Transplanted with Human CD34+ Cells
Nucleofected with Different Sleeping Beauty Vector Components
(A) Analysis of human hematopoietic engraftment determined by the proportion of
human CD45+ cells in the bone marrow of NSG mice transplanted with control
CD34+ cells (Ctrl, not nucleofected, black and white dots or nucleofected without
DNA, gray dots), or with CD34+ cells nucleofected with two different SB vector
component combinations: MC/SB (10 mg Venus MC transposon + 5 mg MC SB
transposase) and MC/SNIM.RNA-SB (10 mg Venus MC transposon + 5 mg RNA SB
transposase). Black dots correspond to cells maintained for 1–2.5 days in culture
before transplantation, whereas white dots correspond to incubations for 4–8 days.
Gray dots correspond to nucleofected cells without DNA and incubated for
1–2.5 days. The gray area represents the limit considered for positive engraftment.
In all instances, mice were analyzed at 3–4 months post-infusion. (B) Analysis of the
percentage of Venus-expressing cells in human hematopoietic cells (CD45+) cor-
responding to animals repopulated with human cells (R1%CD45+ cells in the BMof
mice shown in (A). (C) Percentage of Venus+ cells in the myeloid (CD33+) and
lymphoid (CD19+) population, as well as in hematopoietic progenitors (CD34+)
Molecular Therapy
1146 Molecular Therapy Vol. 26 No 4 April 2018demonstrated in every single transplanted mouse in this particular
experimental group.
DISCUSSION
Owing to their simplicity and inexpensive manufacture, plasmid
DNA vectors remain a common delivery form of the non-viral SB
transposon system in well-transfectable cell types. However, intracel-
lular delivery of plasmid DNA vectors tends to be inefficient and toxic
in some primary cell types, including HSPCs, which compromises the
overall rates of SB-mediated genome modification. In the present
study, we improved stable gene transfer by SB into human HSPCs.
In our first attempts toward enhancing the delivery and integrative
activity of the SB transposon system in HSPCs, we modified conven-
tional SB transposon and transposase plasmid vectors by employing
the MC technology. It allowed us to significantly reduce both SB vec-
tors in size by removing most of the bacterial backbone sequences
from their parental plasmids. The presence of bacterial backbone
elements is mandatory for vector propagation in E. coli, but it is
completely redundant or even undesired for clinical applications.
The first evident advantage of using MC vectors over plasmids was
related to increased cell survival rates following nucleofection of
CD34+ cells (Figure 1). In a molar-to-molar comparison of both plat-
forms, this might be partially explained by a mere reduction of the
total DNA mass due to depletion of bacterial backbone sequences
in both SB MC vectors. However, increased cell viability was also
observed in a weight-to-weight comparison of both delivery plat-
forms, pointing at intrinsic properties of plasmid DNA itself that
possibly induce additional cytotoxicity in vitro. Unmethylated CpG
motifs, which are highly enriched in the bacterial backbone of exog-
enously delivered plasmids, were shown to trigger strong inflamma-
tory responses through Toll-like receptor-935,36 and/or interferon
induction.37 Activation of these cellular sensors might be a conceiv-
able explanation for the observed nucleofection cytotoxicity and,
thus, the exclusion of a large fraction of plasmid DNA-nucleofected
cells from the rest of the proliferating HSPC culture. Indeed, removal
of CpG motifs from plasmid DNA vectors was demonstrated to
reduce inflammatory responses upon pulmonary gene delivery,64
and vector CpG methylation was able to lower immune responsive-
ness toward non-self DNA and led to delayed clearance of transfected
cells in vivo.65
Along with decreased levels of cytotoxicity, nucleofection of HSPCs
with SB transposon components supplied as MCs resulted in
enhanced transient gene delivery and more efficient stable genome
modification as compared to conventional plasmid vectors (Figures
2, 3, and 5). The ultimate success of SB-mediated HSPC genome
modification depends on several parameters, including the efficacycorresponding to animals shown in (B). Data are expressed as mean ± SEM.
Asterisks indicate significant differences as determined by Student’s t test
(*p < 0.05). Each dot represents data obtained from a single NSG-transplanted
recipient. Data from 5 independent experiments are shown.
www.moleculartherapy.orgof cellular entry of the vector, nuclear localization of vector compo-
nents, the levels of transposase expression, and, finally, transposon
excision and integration activity in the nucleus. Although it is difficult
to conclude at which of these gene transfer checkpoints the MC tech-
nology provides the most significant advantage, certain assumptions
can be made. First, it has been speculated that, due to their smaller
size, MC vectors cross cellular membranes more efficiently than plas-
mids.38,41 In electroporation-mediated gene delivery, this would then
be associated with better penetration of MC constructs through the
pores of electro-permeabilized cell membranes.41 Indeed, we
observed an enrichment of Venus+ cells at day 2 post-nucleofection
of MC vectors (Figure 2A). Second, MC vectors may support
enhanced transcription of transgene cassettes. Indeed, enhanced
and sustained transgene expression has been seen in episomal gene
therapy applications with MC vectors, with concomitant gene
silencing commencing rapidly after hydrodynamic injection of
parental plasmid vectors in vivo.43,44 Covalent linkage of bacterial
DNA sequences to a eukaryotic expression cassette has been sug-
gested to facilitate the spreading of repressive chromatin formed pri-
marily on the bacterial backbone, leading in turn to rapid loss of
transgene expression from plasmid DNA vectors.66,67
Importantly, the MC platform led not only to more efficient transient
gene delivery of the SB transposon system but also to greatly
improved SB transposition rates (i.e., stable transgene integration)
into the HSPC genome (Figure 3). The elevated levels of transposition
observed in MC-SB samples are likely supported, at least in part, by
the relatively short, 218-bp distance between the SB transposon
ends in the MC-based transposon vector, owing to the depletion of
the bacterial plasmid backbone. Indeed, SB transposition was shown
to be far more efficient when the length of DNA sequence outside the
transposon unit was shortened, likely by aiding transposon/transpo-
sase complex formation.68
In our efforts toward refinement of the SB transposon system for
stable, non-viral gene transfer into HSPCs, we were able to further in-
crease the rates of transposition by complementing MC-SB transpo-
sons with anmRNA source of the SB100X transposase (Figures 1, 2, 3,
4, and 5). By exploiting the mRNA approach for intracellular delivery,
additional hurdles of gene transfer typical for DNA-based vectors can
be avoided. For example, upon application of an electric pulse, mRNA
translocates into the cytoplasm and is then readily available for
the host translational machinery and protein production. In our
approach for stable gene delivery into HSPCs, we utilized the hyper-
active SB100X transposase and the novel synthetic SNIM.RNA tech-
nology based on uridine and cytidine replacement, resulting in an
increased stability and lower immunogenicity of the produced
mRNA.56 In human HSPCs, a combination of MC-SB transposons
with SNIM.RNA-SB100X supported the highest levels of transposi-
tion and persistent gene delivery (Figure 3).
Importantly, in addition to efficacy, the SB transposon system
refined by combined implementation of MC DNA and SNIM.RNA
technologies also offers several biosafety advantages over conven-tional plasmid DNA vectors. For the MC delivery platform in
particular, the absence of bacterial plasmid backbone elements,
such as antibiotic resistance gene and bacterial origin of replication,
in therapeutic vectors is highly relevant in clinical application.
Especially antibiotic resistance genes included in a therapeutic cell
product and their possible uncontrolled dissemination in patient’s
bacterial flora by horizontal gene transfer following HSPC trans-
plantation may raise safety concerns. In addition, the implementa-
tion of an mRNA source for transient delivery of transposase
component of the SB system further increases the biosafety level
of our approach, as mRNA does not bear the risk of chromosomal
integration. In contrast, it is known that electroporation of plasmid
DNA is associated with a small but non-negligible risk of sponta-
neous vector integration into the host genome.69 Genomic integra-
tion of the SB100X-coding sequence into the HSPC genome
represents a finite risk in a gene therapy application, because such
event could lead to genomic instability due to prolonged and uncon-
trollable transposase expression, resulting in continuous remobiliza-
tion of the already integrated SB transposon.
We addressed biosafety issues of SB-mediated stable gene delivery
into HSPCs also by analyzing the integration profile of SB in
CD34+ cells. Consistent with the results obtained in other cell
types,9–13,70,71 the SB transposon system exhibits a close-to-random
profile of genomic integration in HSPCs (Figure 6). No pronounced
integration preferences could be observed with respect to genes and
various intergenic regions, including TSSs. In contrast, gRV and
lentiviral vectors commonly utilized in gene therapy tend to inte-
grate in a non-random manner. Preferential integrations of gRV
vectors near transcriptional regulatory elements of active
genes60,72,73 and of lentiviral vectors biased toward bodies of genes73
are typically recovered, bearing an increased genotoxicity risk that
already manifested in patients treated with gRV vectors by leuke-
mogenesis during early gene therapy clinical trials.2–5 The fairly
random profile of SB integrations may offer a safer alternative for
lifelong genetic correction of HSPCs.
For gene therapy to be effective it is necessary to (1) achieve robust
delivery of the desired genes to the relevant target cells, (2) express
the genes long term, and (3) minimize the risks of secondary effects.
Non-viral SB transposon-based gene transfer may have certain ad-
vantages over viral vector systems, including limited immunogenicity,
a characteristic random insertion profile, and economical production
of Good Manufactoring Practice (GMP) vector batches for clinical
use. However, non-viral gene transfer approaches typically result in
pronounced cellular toxicity following transfection that limits stable
gene transfer efficiencies in most primary cells. We demonstrated
here a significant improvement in the efficiency of non-viral gene de-
livery into HSPCs by employing both MC DNA and SNIM.RNA
technologies for intracellular delivery and activity of the SB trans-
poson system. Ex vivo transfection of human CD34+ cells with
this enhanced transposon system yielded robust and stable gene
expression, reaching up to 30%–40% of CD34+ cells and CFUs (Fig-
ures 3 and 4).Molecular Therapy Vol. 26 No 4 April 2018 1147
Molecular TherapyOur experiments involving the transplantation of nucleofected
CD34+ cells into immunodeficient mice (Figure 7) first showed that
DNA nucleofection can mediate engraftment defects, consistent
with previous observations.16,74 Nevertheless, maintaining nucleo-
fected cells in culture for 4–8 days limited graft failure and improved
the engraftment of cells expressing the Venus marker gene. The re-
sults were most remarkable when CD34+ cells were nucleofected
with the Venus-MCs and the SB transposase as mRNA. Under these
conditions, 6 of 6 transplantedmice showed high-level engraftment of
CD45+ cells, equivalent to those observed in mice transplanted with
untreated cells. Moreover, in all these cases the presence of Venus+
cells was evident. Because during these days in culture the number
of non-integrated copies of nucleofected constructs is markedly
reduced, our data suggest the convenience of infusing nucleofected
cells after the dilution of unintegrated copies of the transposon vector
system. Most significantly, our results unequivocally demonstrate
that our optimized MC platforms mediate in vivo transgene expres-
sion both in the myeloid and lymphoid lineages, and even in primitive
human hematopoietic CD34+ cells in the bone marrow of trans-
planted mice, demonstrating efficient transposition in primitive he-
matopoietic repopulating cells. Taken together, we consider that
this refined delivery platform of the SB transposon system constitutes
a highly promising approach to be implemented for the clinical use of
non-viral hematopoietic gene therapy.
MATERIALS AND METHODS
Generation and Production of SB Transposon and Transposase
Minicircle DNA Constructs
In the present work, we utilized a ParA resolvase-based recombination
system as an effective platform for large-scale and clinically relevant
MC production.39,75,76 The production of MC DNA is carried out in
two major steps: the cultivation in a bioreactor and the purification
by specific chromatographic steps. Cultivation of MC producer
E. coliK12 cellswas carried out at 37C in a Sartorius-Stedimbioreactor
BiostatC plus (Sartorius-Stedim, Guxhagen, Germany) with 10 or 20 L
working volume used without addition of any antibiotics and grown in
Luria-Bertani (LB) medium for approximately 15 hr. The recombinase
expression was induced at an OD600 » 4 by adding L-arabinose. After
1 hr of further growth, cells were harvested by centrifugation, frozen,
andDNAwas purified, as described previously.39,77 The recombination
product (MC andmini-plasmid) was further purified after the primary
recovery with a non-commercial proprietary affinity chromatography
matrix39 to specifically bind the MC and remove the other DNA mol-
ecules from the preparation. The specific binding ofMCDNAwas opti-
mized with different ionic strength and pH values. The resulting MC
was subject to multiple quality control tests to establish that the DNA
was free of LPS-endotoxin, protein, RNA, and bacterial chromosomal
DNA and that the MC was a homogeneous monomer (no multimers)
in a supercoiled conformation.
Generation of SB Transposase in the Form of SNIM.RNA
The SB100X-coding sequences were excised from the expression
plasmid pcGlobin2-SB100X22 using BamHI-EcoRI and cloned into
the respective sites of pVAXA120.56 This vector is identical to1148 Molecular Therapy Vol. 26 No 4 April 2018pVAX1 (Invitrogen) with the exception of a stretch of 120 As between
the PstI-NotI sites. Template DNA for the construct pVAXA120-
SB100X was prepared using the Maxiprep kit from Macherey
and Nagel. To generate template for in vitro transcription (IVT),
pVAXA120-SB100X was linearized by restriction digestion using
NotI. Linearized template plasmid DNA (pDNA) was further purified
by chloroform ethanol sodium acetate purification. IVT was carried
out using Ethris’ proprietary IVT reaction mixture including T7
RNA polymerase, in which 25% of Cytidine-50-Triphosphate and
Uridine-50-Triphosphate was replaced by 5-Methylcytidine-
50-Triphosphate and 2-Thiouridine-50-Triphosphate (Jena Biosci-
ences, Germany). Capping of the resulting cmRNA (chemically
modified RNA) was performed using Vaccinia virus-capping enzyme
and mRNA Cap 20-O-Methyltransferase to generate a cap 1 structure.
The mRNA was subsequently purified by ammonium acetate precip-
itation. Size and quality of the produced cmRNA was confirmed by
Experion LabChip analysis.
Purification and Cultivation of CD34+ Cells
The in vitro experiments shown in Figures 1, 2, 3, 4, 5, and 6 were
done with CD34+ cells isolated from apheresis products collected af-
ter peripheral blood stem cell mobilization induced bymeans of injec-
tions of granulocyte colony-stimulating factor. Apheresis products
were obtained from three independent healthy donors after informed
consent and with approval of the responsible Ethics Committee
(Goethe University, Permit 329/10). Apheresis harvest was first sub-
jected to red blood cell lysis using ACK Buffer (Invitrogen) and then
to positive selection by magnetic cell separation using the MACS hu-
man CD34 MicroBead Kit, MACS separator, and MACS LS columns
(Miltenyi Biotec), according to the manufacturer’s instructions. Prior
to nucleofection, CD34+ cells were stimulated for 1.5–2.5 days in
complete StemSpan serum-free medium (STEMCELL Technologies),
which was supplemented with 2 mM L-glutamine and the following
cytokine cocktail: 100 ng/mL human stem cell factor (hSCF),
100 ng/mL hFlt3-Ligand, and 100 ng/mL thrombopoietin (TPO)
(PeproTech). Afterward, cell culture medium was gradually shifted
to X-VIVO 20 (Lonza) supplemented with 2 mM L-glutamine and
the same cytokine cocktail as described above. For long-term analysis,
cells were maintained under standard cell culture conditions at a cell
density of 0.5–1  106/mL until up to day 62 post-nucleofection.
The in vivo transplantation experiments shown in Figure 7 were done
with cord blood-derived CD34+ cells. Cord blood samples from
healthy donors were obtained from the Madrid Community Transfu-
sion Centre after informed consent of the mothers and under their
institutional review board (IRB) approval and complying with the
Helsinki Declaration. Mononuclear cells were purified by Ficoll-
Paque PLUS (GE Healthcare, Fairfield, CT, USA) density gradient
centrifugation, and CD34+ magnetic-labeled cells were selected using
CD34 MicroBead Kit.
Nucleofection of CD34+ Cells
1  106 cells per sample were nucleofected with 10 mg SB transposon
and 5 mg SB transposase construct, both provided either in plasmid
www.moleculartherapy.orgDNA or MC DNA form. In a mass-to-mass comparison, equal
amounts of both MC SB vectors in relation to their plasmid counter-
parts were tested; in an equimolar comparison, the amount of both
MC SB vectors was adjusted in order to provide the same numbers
of vector particles as in the plasmid sample. Since one of our objec-
tives was to reduce DNA amount-dependent nucleofection toxicity,
no compensation with filler DNAwas applied. In some control exper-
iments, cells were nucleofected with 10 mg SB transposon alone or
were subjected to nucleofection without DNA. In SNIM.RNA-based
gene delivery experiments, the DNA vector carrying the SB100X
transposase was replaced by 5 or 10 mg SNIM.RNA-SB. Cells were
nucleofected using the 4D Nucleofector (Lonza) and E0100 program.
After nucleofection, cells were resuspended in 2 mL complete
StemSpan medium.
Flow Cytometry
Efficiency of transient and stable gene delivery was estimated by
flow cytometry at days 2 and 15 post-nucleofection, respectively.
Cell viability was determined at day 2 post-nucleofection. For
that, around 1/10 of cell culture volume was collected, washed
with PBS, and stained with DAPI/PBS solution. The cells were
then subjected to flow cytometry using the BD LSR II Flow Cytom-
eter (BD Biosciences). Gating for Venus signal was accomplished
within the DAPI-negative cell population. The results were analyzed
using the FCS Express 4 Flow Cytometry software (De Novo
Software).
CFU Assay
Committed hematopoietic progenitors were quantified in vitro at day
2 post-nucleofection by seeding 4,000–4,500 purified CD34+ cells/mL
in methylcellulose medium MethoCult H4434 Classic (STEMCELL
Technologies) enriched with a cytokine cocktail supporting the
formation of BFU-E, CFU-E, CFU-GM, and CFU-GEMM. After
15 days of culture, hematopoietic colonies of different phenotypes
were morphologically identified and counted using a Nikon Eclipse
Ti-S microscope. Representative images of each type of cell colony
were taken with a monochromatic camera using the 10 objective
and the NIS Elements software (Nikon).
Transplants of NSG Mice
NSG mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA) and maintained at the CIEMAT animal facility (registra-
tion 28079-21 A). All experimental procedures were carried out
according to European Directive 2010/63/UE on the use and protec-
tion of mammals used for experimentation and other scientific
purposes. NSG mice were irradiated with 1.5 Gy 24 hr prior to
transplantation. The 0.7–1  106 CD34+ cells, or their equivalent
cell products generated after cell expansion in complete StemSpan
medium, were transplanted into NSG mice. Transplanted mice
were culled at 3–4 months post-transplantation (mpt) and total
bone marrow cells (BMCs) were analyzed by flow cytometry
with hCD45 (304014, BioLegend), huCD19 (25-0198, eBioscience),
hCD33 (A07775, Beckman Coulter), and hCD34 (555824, Becton
Dickinson) monoclonal antibodies.Real-Time PCR
Quantification of genomic VCN within the bulk cell population was
performed by real-time PCR after 3 weeks of cell culture expansion.
Genomic DNA (gDNA) was isolated using the DNeasy Blood & Tis-
sue Kit (QIAGEN) according to the manufacturer’s instructions. To
exclude residual plasmid DNA from the DNA isolates, the samples
were subjected to an overnight restriction digestion at 37C using
methylation-sensitive DpnI restriction enzyme. The digest was then
separated in an 0.8% agarose gel. The band representing the gDNA
was cut out, and gDNA was purified with Zymoclean Large Fragment
DNA Recovery Kit (Zymo Research). Real-time PCR was performed
in triplicates using the KAPA SYBR FAST Universal kit (PeqLab) and
the LightCycler (Roche). Genomic integrants of the SB transposon
were detected using SB-IRDR-R_FW: 50-GCTGAAATGAATCAT
TCTCTCTACTATTATTCTGA-30 and SB-IRDR-R_RV: 50-AATT
CCCTGTCTTAGGTCAGTTAGGA-30 primers. The gDNA content
was normalized based on the amplification of the TERT gene using
TERT_FW: 50-GACAAAGTACAGCTCAGGCG-30 and TERT_RV:
50-TTCAGCGTGCTCAACTACGA-30 primers. PCR conditions
were as follows: 95C for 10 min and 45 cycles of 95C for 10 s,
60C for 20 s, and 72C for 10 s. The final VCN was determined
using clonal gDNA standards carrying a defined number of genomic
insertions of an SB transposon. Results were analyzed using the
LightCycler 96 Software (Roche).
Droplet Digital PCR
Quantification of genomic VCN from cell colonies was performed by
droplet digital PCR after at least 3 weeks of colony growth inmethylcel-
lulose medium. Individual colonies derived from 3 independent exper-
iments were picked, and gDNA was isolated using the Quick-gDNA
MicroPrep (Zymo Research). To exclude residual plasmid DNA from
the gDNA amplification template, the obtained DNA fraction was sub-
jected to an overnight digestion at 37C using methylation-sensitive
DpnI restriction enzyme. Afterward, gDNA was fragmented by a 2-hr
digestion at 25C using CviQI restriction enzyme. Quantification of
genomic VCN was performed using the QX100 Droplet Digital PCR
System (Bio-Rad) and ddPCR Supermix for Probes (Bio-Rad). The
SB integrants were detected by amplification of transposon’s right
inverted repeats (RIRs) using RIR_FW: 50-GAATGTGATGAAAGAA
ATAAA-30 and RIR_RV: 50-AGTTTACATACACCTTAGCC-30
primers and the RIR-specific probe: 50-FAM-TGGTGATCCTAACT
GACCTAAGACAGG-BH1-30. The results were normalized based on
the amplification of the RPP30 gene using RPP30_FW: 50-GGTTAAC
TACAGCTCCCAGC-30 and RPP30_RV: 50-CTGTCTCCACAAGT
CCGC-30 primers. The 50-HEX-TGGACCTGCGAGCGGGTTCTGA
CC-BH1-30 probe served then for detection of RPP30 amplicons.
PCR conditions were as follows: 95C for 10 min; 40 cycles of 94C
for 10 s, 53C for 20 s, and 60C for 10 s; and 98C for 10 min. The re-
sults were analyzed using the QuantaSoft software (Bio-Rad).
Insertion Site Library Preparation and Bioinformatic Analysis
The preparation of the Illumina sequencing-compatible insertion
site libraries was described earlier.13 Briefly, agarose gel-purified
high molecular gDNA was sonicated to an average size ofMolecular Therapy Vol. 26 No 4 April 2018 1149
Molecular Therapy500 bp and ligated to custom linkers, and nested PCR reactions
were used to generate multiplexed libraries containing the trans-
poson ends and flanking genomic sequences for Illumina HiSeq
sequencing. The conditions and thresholds of the raw read pro-
cessing and mapping parameters have been specified previously.13
In short, the raw reads were subjected to quality trimming, and
the resulting reads were mapped to the hg19 human genome as-
sembly with bowtie78 in cycling mapping using the TAPDANCE
algorithm.79
For the comparative analysis with SB integration profile, we used gRV
and lentiviral insertion site datasets produced by linker-mediated
PCR (LM-PCR) coupled to Roche-454 pyrosequencing from human
cord blood-derived CD34+ HSPCs, as previously described.60 Addi-
tional lentiviral integration sites were obtained from the same
cell sample by adapting the LM-PCR technique to Illumina MiSeq
sequencing. Essentially, the nested primers were flanked by the
following sequences: 50-TCGTCGGCAGCGTCAGATGTGTATAA
GAGACA-(viral LTR-nested primer) and 50-GTCTCGTGGGCTCG
GAGATGTGTATAAGAGACAG-linker-nested primer). MiSeq v3
reagents were used to sequence the LM-PCR library at saturation-
producing paired-end 300-bp reads, following the standard
operational instructions. Trimming of the sequencing reads was
performed by bowtie,78 and the sequence mapping onto the human
reference genome (hg19 assembly) was performed as previously
described.60
Genomic segmentation and whole-transcriptome RNA sequencing
(RNA-seq) datasets for human HSPCs were obtained from the
NIH Roadmap Epigenomics Mapping Consortium.61 Analyses of
the representation of the insertions in genomic regions of interest
were done in R using the genomation package.80 For the correla-
tion of gene expression levels and insertion frequencies, reads
per kilobase per million mapped reads (RPKM) values of all
known, non-redundant human transcription units were used to
group the genes to ten pools of equal size with increasing
expression values. For the analysis of insertions in GSHs, the
corresponding genomic coordinates were downloaded from the
UCSC Genome Browser database (http://genome.ucsc.edu/cgi-bin/
hgTables?command=start); for the genes implicated in cancer, we
used the AllOnco collection.63
To measure the association of the vector insertions with active genes
involved in known human disease phenotypes,81 we selected all inser-
tions within gene bodies and in segments up to 10 kb upstream of the
TSSs of expressed protein-coding genes in human HSPCs. Genes
were designated as transcriptionally active with RPKM values greater
than or equal to the first quantile of the count range. Lists of these
vector insertions were analyzed with the Genomic Regions Enrich-
ment of Annotations Tool (GREAT) algorithm82 using default
settings. Associations with human phenotypes were considered statis-
tically significant if both the binomial test over genomic regions and a
hypergeometric test over genes resulted in false discovery rate (FDR)
Q-values% 0.05.1150 Molecular Therapy Vol. 26 No 4 April 2018Statistical Analysis
For all statistical analyses, significance was set as *0.01 % p % 0.05
and **0.001% p% 0.01 throughout the experiments. For correlation
analysis, we performed a Pearson correlation after checking the
Gaussian distribution of the sampled data using D’Agostino and
Pearson, Shapiro-Wilk, and Kolmogorov-Smirnov normality tests.
Two-tailed p value was computed in all cases.
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Supplementary	  Figure	  S1.	  Minicircle	  Sleeping	  Beauty	   transposon	  vectors.	  a)	  Agarose	  gel	  electrophoresis	  of	  the	  
minicircle	  MC.T2-­‐CAGGS-­‐Venus	  (MC1390).	  Lanes	  M:	  1-­‐kb	  DNA	  size	  marker	  (PlasmidFactory	  Item	  no.	  MSM-­‐865-­‐50),	  
lanes	   1,2:	   undigested	  minicircle	   DNA	   almost	  monomeric	   supercoiled	   form,	   lanes	   3,4:	  minicircle	   DNA	   linearized	  
with	  PmeI	  (NEB)	  to	  determine	  the	  size	  (appr.	  3.4	  kb).	  b)	  Agarose	  gel	  electrophoresis	  of	  the	  minicircle	  MC.SB100X	  
(MC1420).	   Lanes	   M:	   1-­‐kb	   DNA	   size	   marker	   (PlasmidFactory	   Item	   no.	   MSM-­‐865-­‐50),	   lanes	   1,2:	   undigested	  
minicircle	   DNA	   almost	   monomeric	   supercoiled	   form,	   lanes	   3,4:	   minicircle	   DNA	   linearized	   with	   PacI	   (NEB)	   to	  
determine	  the	  size	  (appr.	  2.3	  kb).	  
Supplementary	   Figure	   S2.	   Long-­‐term	   persistence	   of	   transgene	  
expression	   in	   CD34+	   cells	   following	   Sleeping	   Beauty	   transposon-­‐
mediated	   stable	   gene	   delivery	   in	   vitro.	   Percentages	   of	   Venus-­‐
expressing	  cells	  aXer	  nucleofecYon	  	  of	  CD34+	  cells	  with	  (MC-­‐SB	  10+5)	  or	  
without	  (MC-­‐SB	  10+0)	  SB	  transposase.	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Supplementary	   Figure	   S3.	   ComparaDve	   numbers	   of	   colonies	  
generated	  aEer	  nucleofecDon	  of	  CD34+	  cells	  determined	  by	  CFU	  
assays.	   Numbers	   of	   total	   CFUs	   aXer	   seeding	   of	   4,000-­‐4,500	  
purified	  CD34+	  cells	  following	  nucleofecYon	  with	  MC	  DNA	  only	  and	  
with	  MC	  DNA/SNIM.RNA	  are	  shown.	  Data	  are	  expressed	  as	  means	  
±	  SEM;	  n	  =	  3	  per	  group.	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Supplementary	   Figure	   S4.	   Sequence	   logo	   of	   Sleeping	   Beauty	  
inserDon	  sites	  in	  CD34+	  cells.	  The	  figure	  was	  generated	  on	  the	  base	  
frequency	  matrix	  of	  genomic	  sequences	  immediately	  flanking	  the	  SB	  
inserYon	  sites	  in	  HCSs	  using	  the	  seqLogo	  package	  in	  R.	  
Supplementary	   Figure	   S5.	   DistribuDon	   of	   Sleeping	   Beauty	   transposon,	   MLV-­‐derived	   gammaretroviral	   and	  
HIV-­‐1-­‐derived	   lenDviral	   integrants	   in	   a	   25-­‐state	   chromaDn	   segmentaDon	   dataset	   of	   CD34+	   cells.	   Color	  
intensiYes	  depict	  the	  degree	  of	  deviaYon	  from	  the	  expected	  random	  distribuYon.	  The	  cladogram	  was	  drawn	  on	  
the	  basis	  of	  row	  means.	  The	  abbreviaYons	  stand	  for	  the	  following	  genomic	  states:	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  Transcribed	  -­‐	  5'	  preferenYal	  
Tx 	  Strong	  transcripYon	  
Tx3 	  Transcribed	  -­‐	  3'	  preferenYal	  
TxWk 	  Weak	  transcripYon	  
TxReg 	  Transcribed	  &	  regulatory	  (Prom/Enh)	  
TxEnh5 	  Transcribed	  5'	  preferenYal	  and	  Enh	  
TxEnh3 	  Transcribed	  3'	  preferenYal	  and	  Enh	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  Transcribed	  and	  Weak	  Enhancer	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Supplementary	   Figure	   S6.	  Viral	   gene	   vector	   inserDons	   have	   a	   tendency	   to	   associate	  with	   genes	  
also	   linked	   to	   human	   disease.	   Shown	   are	   the	   staYsYcally	   most	   significant	   human	   phenotype	  
ontology	   categories	   in	   associaYon	  with	   vector	   inserYons	  within	   expressed	   genes	   of	   human	  HSCs.	  
The	  GREAT	  algorithm1	  was	  used	  to	  calculate	  associaYon	  based	  on	  two	  measures	  of	  enrichment:	  a	  
binomial	   test	  over	   genomic	   regions	  and	  a	  hypergeometric	   test	  over	   genes.	  Any	   target	   region	  was	  
considered	   staYsYcally	   significant	   if	   the	   FDR	   Q-­‐values	   for	   both	   staYsYcal	   tests	   were	   <=	   0.05.	  
Asterisks	  mark	  phenotypes	  related	  to	  hematopoieYc	  funcYons.	  	  
1.	  McLean	  CY,	  Bristor	  D,	  Hiller	  M,	  et	  al.	  GREAT	   improves	   funcYonal	   interpretaYon	  of	  cis-­‐regulatory	  
regions.	  Nature	  biotechnology.	  2010;28(5):495-­‐501.	  
Supplementary	  Figure	  S7:	  RepresentaYve	  analyses	  showing	  the	  expression	  of	  the	  Venus	  marker	  gene	  
in	  human	  myeloid	  (CD33),	  lymphoid	  (CD19)	  and	  CD34+	  cells	  engraXing	  NSG	  mice.	  Data	  correspond	  to	  
one	  mouse	  transplanted	  with	  cells	  nucleofected	  with	  the	  MC/SNIM.RNA-­‐SB	  constructs.	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